Gastroenterology Research, ISSN 1918-2805 print, 1918-2813 online, Open Access
Article copyright, the authors; Journal compilation copyright, Gastroenterol Res and Elmer Press Inc
Journal website http://www.gastrores.org

Original Article

Volume 12, Number 3, June 2019, pages 148-156

Efficacy of Low Dose Chemoprophylaxis for Coccidioidomycosis Infection in Liver Transplant Recipients

Figures

Figure 1.
Figure 1. Patient population.
Figure 2.
Figure 2. Post-transplant coccidioidomycosis status compared with prophylaxis dose.
Figure 3.
Figure 3. Post-transplant coccidioidomycosis status compared with pre-transplant status.
Figure 4.
Figure 4. Post-transplant coccidioidomycosis status compared with prophylaxis duration.
Figure 5.
Figure 5. Survival based on antifungal prophylaxis dose.
Figure 6.
Figure 6. Survival based on coccidioidomycosis evaluation post-transplant.

Table

Table 1. Sample Baseline Demographics
 
Baseline characteristicsTotal number (n = 78)Standard dose (n = 11)Low dose (n = 67)P-value
*Weight and BMI calculated before the time of transplant. **Pre-transplant. BMI: body mass index; ESLD: end-stage liver disease; HCV: hepatitis C virus; HBV: hepatitis B virus; NASH: non-alcoholic steatohepatitis; DM: diabetes mellitus; HTN: hypertension; Ab: antibody.
Age in years (range 6 months to 68 years)
  < 18 years33 (42.3%)7 (63.6%)26 (38.8%)NS
  ≥ 18 years45 (57.7%)4 (36.4%)41 (61.2%)
Mean age18.934.3NS
Gender
  Male46 (59.0%)5 (45.5%)41 (61.2%)NS
  Female32 (41.0%)6 (54.5%)26 (38.8%)
Race
  White29 (37.2%)2 (18.2%)27 (40.3%)NS
  Non-white49 (62.8%)9 (81.8%)40 (59.7%)
ESLD etiology
  Alcoholic8 (10.3%)0 (00.0%)8 (11.9%)NS
  HCV22 (28.2%)2 (18.2%)20 (29.9%)
  HBV1 (1.3%)0 (0.00%)1 (1.5%)
  NASH9 (11.5%)1 (9.1%)8 (11.9%)
  Other38 (48.7%)8 (72.7%)30 (44.8%)
Weight in pounds, mean*70.5136.90.01
BMI, mean*19.426.00.01
History of DM**17 (22.1%)1 (10.0%)16 (23.9%)NS
History of HTN**17 (22.4%)3 (30.0%)14 (21.2%)NS
History of cancer**20 (26.3%)3 (30.0%)17 (25.8%)NS
Immunosuppression
  Tacrolimus67 (88.2%)9 (90.0%)58 (87.9%)NS
  Prednisone58 (76.3%)9 (81.8%)49 (75.4%)NS
  Mycophenolate mofetil59 (78.7%)7 (70.0%)52 (80.0%)NS
  Sirolimus6 (8.1%)1 (10.0%)5 (7.8%)NS
  Induction therapy29 (59.2%)1 (33.3%)28 (60.9%)NS
Rejection
  Monoclonal Ab beyond 30 days of transplant4 (9.8%)0 (0.00%)4 (11.1%)NS
  Steroid bolus30 (73.2%)2 (40.0%)28 (77.8%)NS